1Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom' s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(12) :1570-1575.
2Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractoy Waldenstrom's macroglobulinemla:rusults of WMCTG Trial 03-248[J]. Clin Cancer Res,2007,13(11) :3320-3325.
3Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refratory Waldenstrom' s macroglobulinemia with bortezomib[J]. Haematologica, 2005, 90(12):1655-1658.
4Mitsiades CS, Mitsiades N, Richardson PG, et ah Novel biologically based therapies for Waldenstrom s maeroglobulinemia[J]. Semin Oncol, 2003,30 ( 2 ) : 309-312.
5Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma:the National Cancer Institute of Canada Clinical Trials Group trial IND. 150[J]. Ann Oncol,2007,18(1) :116-121.
2Owen R G, Treon S P, A1 Katib A, et al. Clinicopatho- logical definition of Waldenstrom "s macroglobulinemia: consensus panel recommendations from the Second Inter- national Workshop on Waldenstrom "s Macroglobulinemia [J]. Semin Oncol, 2003,30(2) :110-115.
3Treon S P, Hunter Z R, Aggarwal A, et al. Characteriza- tion of familial Waldenstroms macroglobulinemia[ J]. Ann Oncol, 2006,17 ( 3 ) :488-494.
4Ansell S M, Kyle R A, Reeder C B, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted thera- py (mSMART) guidelines[ J]. Mayo Clin Proc, 2010,85 (9) :824-833.
5Gertz M A, Merhni G, Treon S P. Amyloidosis and Wal- denstrom "s macroglobulinemia [ J ]. Hematology ( Am Soc Hematol Educ Program) , 2004:257-282.
6Gertz M A. Waldenstrom macroglobulinemia [ J]. Hema- tology, 2012,17 ( Suppl 1 ) : 112-116.
7Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005 [ J]. Leuk Lymphoma, 2012,53 ( 8 ) : 1625-1626.
8Gertz M A. Waldenstrom macroglobulinemia: 2013 up- date on diagnosis, risk stratification, and management [J]. Am J Hematol, 2013,88(8) :703-711.
9Graziani M, Merlini G, Petrini C. Guidelines for the a- nalysis of Bence Jones protein [ J ]. Clin Chem Lab Med, 2003,41 ( 3 ) :338-346.
10International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple mye- loma and related disorders: a report of the International Myeloma Working Group [ J]. Br J Haematol, 2003,121 (5) :749-757.
